

typographical error. The Examiner's suggested rephrasing at the end of those claims has been entered.

With respect to the Examiner's objection of claim 31, the Applicants have amended that claim to remove the recitation of "3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a] pyrimidin-6-ylmethyl)-1-methylpyridinium chloride," which was not included in original claim 30.


In view of the foregoing amendments and remarks, Applicants respectfully request the reconsideration and continued examination of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: October 2, 2002

By:   
Russell L. Sandidge  
Reg. No. 36,911

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com